Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

MN Gandy; M McIldowie; K Lewis; AM Wasik; D Salomonczyk; K Wagg; ZA Millar; D Tindiglia; P Huot; T Johnston; S Thiele; B Nguyen; Nicholas Barnes; JM Brotchie; MT Martin-Iverson; J Nash; John Gordon; MJ Piggott

doi:10.1039/c0md00108b

Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

MN Gandy, M McIldowie, K Lewis, AM Wasik, D Salomonczyk, K Wagg, ZA Millar, D Tindiglia, P Huot, T Johnston, S Thiele, B Nguyen, Nicholas Barnes, JM Brotchie, MT Martin-Iverson, J Nash, John Gordon, MJ Piggott

Research output: Contribution to journal › Article

12 Citations (Scopus)

Abstract

Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel alpha-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

Original language	English
Pages (from-to)	287-293
Number of pages	7
Journal	Medchemcomm
Volume	1
Issue number	4
Early online date	7 Sept 2010
DOIs	https://doi.org/10.1039/c0md00108b
Publication status	Published - 1 Oct 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c0md00108b

Cite this

Gandy, MN., McIldowie, M., Lewis, K., Wasik, AM., Salomonczyk, D., Wagg, K., Millar, ZA., Tindiglia, D., Huot, P., Johnston, T., Thiele, S., Nguyen, B., Barnes, N., Brotchie, JM., Martin-Iverson, MT., Nash, J., Gordon, J., & Piggott, MJ. (2010). Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity. Medchemcomm, 1(4), 287-293. https://doi.org/10.1039/c0md00108b

@article{5e67524a3db04c1ba234d7cc2dabc9e1,

title = "Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity",

abstract = "Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel alpha-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.",

author = "MN Gandy and M McIldowie and K Lewis and AM Wasik and D Salomonczyk and K Wagg and ZA Millar and D Tindiglia and P Huot and T Johnston and S Thiele and B Nguyen and Nicholas Barnes and JM Brotchie and MT Martin-Iverson and J Nash and John Gordon and MJ Piggott",

year = "2010",

month = oct,

day = "1",

doi = "10.1039/c0md00108b",

language = "English",

volume = "1",

pages = "287--293",

journal = "Medchemcomm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "4",

}

Gandy, MN, McIldowie, M, Lewis, K, Wasik, AM, Salomonczyk, D, Wagg, K, Millar, ZA, Tindiglia, D, Huot, P, Johnston, T, Thiele, S, Nguyen, B, Barnes, N, Brotchie, JM, Martin-Iverson, MT, Nash, J, Gordon, J & Piggott, MJ 2010, 'Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity', Medchemcomm, vol. 1, no. 4, pp. 287-293. https://doi.org/10.1039/c0md00108b

TY - JOUR

T1 - Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

AU - Gandy, MN

AU - McIldowie, M

AU - Lewis, K

AU - Wasik, AM

AU - Salomonczyk, D

AU - Wagg, K

AU - Millar, ZA

AU - Tindiglia, D

AU - Huot, P

AU - Johnston, T

AU - Thiele, S

AU - Nguyen, B

AU - Barnes, Nicholas

AU - Brotchie, JM

AU - Martin-Iverson, MT

AU - Nash, J

AU - Gordon, John

AU - Piggott, MJ

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel alpha-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

AB - Burkitt's lymphoma (BL) is a particularly aggressive cancer that primarily affects African children. Unfortunately, effective and affordable treatment is out of reach of most of the afflicted. The illicit psychoactive drug methylenedioxymethamphetamine (MDMA, 'ecstasy') is cytotoxic to BL cell lines, but its low potency, psychoactivity and neurotoxicity preclude consideration as a therapeutic drug candidate. This paper describes the discovery of novel alpha-aryl analogues of MDMA that lack psychoactivity and reduce BL cell line viability with significantly more potency than the lead compound. Preliminary in vitro studies also indicate that the compounds are non-toxic to a relevant neuronal cell line.

U2 - 10.1039/c0md00108b

DO - 10.1039/c0md00108b

M3 - Article

SN - 2040-2503

VL - 1

SP - 287

EP - 293

JO - Medchemcomm

JF - Medchemcomm

IS - 4

ER -

Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this